Charles River Laboratories International, Inc. (CRL): who owns it and who trades it
As of Nov 16, 2026, CRL insiders reported 21 open-market sales worth $52.1M and 2 purchases worth $7.3K in the last 12 months, with 94% of the sale value made under pre-set 10b5-1 plans. The largest seller was James C Foster (Director), with $43.3M. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Charles River Laboratories International
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CRL
565 funds and institutions reported CRL shares worth $13B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 8.8%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 4.24M | 8.80% | $962M | +23% |
| BlackRock, Inc. | 3.80M | 7.89% | $861M | -2% |
| Vanguard Capital Management LLC | 3.15M | 6.54% | $714M | -2% |
| Invesco Ltd. | 2.98M | 6.20% | $677M | +25% |
| Harris Associates L P | 2.24M | 4.65% | $508M | +4% |
| Vanguard Portfolio Management LLC | 2.21M | 4.59% | $501M | -4% |
| Allspring Global Investments Holdings, LLC | 1.91M | 3.96% | $436M | -4% |
| State Street Corp | 1.86M | 3.87% | $423M | -0% |
| Dimensional Fund Advisors LP | 1.65M | 3.42% | $374M | -0% |
| Ariel Investments, LLC | 1.51M | 3.13% | $342M | +4% |
| T. Rowe Price Associates | 1.51M | 3.13% | $341M | +34% |
| Geode Capital Management, LLC | 1.31M | 2.71% | $296M | No change |
| Wellington Management Group LLP | 1.29M | 2.67% | $292M | -21% |
| Citadel Advisors LLC | 1.19M | 2.48% | $271M | -2% |
| Bank of America Corp | 1.17M | 2.43% | $266M | +3% |
| Earnest Partners LLC | 1.12M | 2.33% | $254M | +15% |
| Ameriprise Financial Inc | 881,189 | 1.83% | $200M | -21% |
| Neuberger Berman Group LLC | 862,704 | 1.79% | $196M | -1% |
| Sei Investments Co | 813,530 | 1.69% | $184M | +7% |
| Morgan Stanley | 800,487 | 1.66% | $182M | -3% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CRL insiders reported $7.3K of open-market purchases and $52.1M of sales. 94% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 22, 2026 | James C Foster | Director | Sale plan | 24,042 | $350.00 | $8.4M | Form 4 |
| Oct 21, 2026 | Shannon M Parisotto | CEVP | Sale plan | 2,156 | $344.41 | $743K | Form 4 |
| Oct 5, 2026 | Shannon M Parisotto | CEVP | Sale plan | 981 | $308.44 | $303K | Form 4 |
| Sep 30, 2026 | Glenn Coleman | CFO | Purchase | 10 | $297.43 | $3K | Form 4 |
| Aug 25, 2026 | James C Foster | Director | Sale plan | 33,561 | $300.00 | $10.1M | Form 4 |
| Aug 19, 2026 | Shannon M Parisotto | CEVP | Sale plan | 2,039 | $294.12 | $600K | Form 4 |
| Aug 18, 2026 | Nancy C Andrews | Director | Sale | 573 | $285.24 | $163K | Form 4 |
| Aug 11, 2026 | Birgit Girshick | CEO | Sale plan | 6,500 | $279.90 | $1.8M | Form 4 |
| Aug 11, 2026 | Shannon M Parisotto | CEVP | Sale plan | 3,714 | $279.66 | $1M | Form 4 |
| Aug 10, 2026 | James C Foster | Director | Sale plan | 28,733 | $275.00 | $7.9M | Form 4 |
| Aug 6, 2026 | Michael Gunnar Knell | Vice president | Sale | 1,274 | $259.07 | $330K | Form 4 |
| Aug 6, 2026 | Michael Gunnar Knell | Vice president | Sale | 901 | $260.63 | $235K | Form 4 |
| Aug 6, 2026 | Michael Gunnar Knell | Vice president | Sale | 810 | $261.45 | $212K | Form 4 |
| Aug 6, 2026 | Michael Gunnar Knell | Vice president | Sale | 213 | $262.37 | $55.9K | Form 4 |
| Aug 6, 2026 | Michael Gunnar Knell | Vice president | Sale | 620 | $263.94 | $164K | Form 4 |
| Aug 6, 2026 | Michael Gunnar Knell | Vice president | Sale | 736 | $258.53 | $190K | Form 4 |
| Aug 6, 2026 | Michael Gunnar Knell | Vice president | Sale | 404 | $258.53 | $104K | Form 4 |
| Aug 6, 2026 | Michael Gunnar Knell | Vice president | Sale | 1,205 | $258.53 | $312K | Form 4 |
| Aug 6, 2026 | Michael Gunnar Knell | Vice president | Sale | 482 | $265.17 | $128K | Form 4 |
| Aug 6, 2026 | Victoria L Creamer | Vice president | Sale | 4,179 | $259.16 | $1.1M | Form 4 |
| Aug 5, 2026 | Shannon M Parisotto | CEVP | Sale plan | 5,046 | $263.00 | $1.3M | Form 4 |
| Jun 29, 2026 | James C Foster | Director | Sale plan | 75,000 | $225.00 | $16.9M | Form 4 |
| Mar 3, 2026 | Joseph W LaPlume | Vice president | Purchase | 25 | $174.54 | $4.4K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| James C Foster | Director | – | $43.3M | Oct 22, 2026 |
| Shannon M Parisotto | CEVP, Disc & Safety Assessment | – | $4M | Oct 21, 2026 |
| Birgit Girshick | Chief Executive Officer, Director | – | $1.8M | Aug 11, 2026 |
| Michael Gunnar Knell | SVP, Finance and CAO | – | $1.7M | Aug 6, 2026 |
| Victoria L Creamer | EVP & Chief People Officer | – | $1.1M | Aug 6, 2026 |
| Nancy C Andrews | Director | – | $163K | Aug 18, 2026 |
| Joseph W LaPlume | EVP, Corp Strategy & Develop | $4.4K | – | Mar 3, 2026 |
| Glenn Coleman | EVP & Chief Financial Officer | $3K | – | Sep 30, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CRL short interest
Moderate short interest. 6.2% of CRL shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short went down 18%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.99M CRL shares were sold short, 6.2% of the shares outstanding, up 5.4% from the report before. At the average daily volume of 1.34M shares, buying them all back would take about 2.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.99M | 6.23% | +5% | 1.34M | 2.2 |
| Oct 15, 2026 | 2.83M | 5.94% | -2% | 978,530 | 2.9 |
| Sep 30, 2026 | 2.88M | 6.03% | +29% | 1.07M | 2.7 |
| Sep 15, 2026 | 2.23M | 4.67% | -12% | 811,691 | 2.8 |
| Aug 31, 2026 | 2.54M | 5.31% | +7% | 913,007 | 2.8 |
| Aug 14, 2026 | 2.36M | 4.95% | -31% | 1.06M | 2.2 |
| Jul 31, 2026 | 3.42M | 7.16% | +2% | 841,792 | 4.1 |
| Jul 15, 2026 | 3.34M | 6.94% | -23% | 837,232 | 4.0 |
| Jun 30, 2026 | 4.35M | 9.04% | +21% | 1.02M | 4.3 |
| Jun 15, 2026 | 3.61M | 7.50% | -7% | 690,301 | 5.2 |
| May 29, 2026 | 3.90M | 8.09% | +7% | 1.08M | 3.6 |
| May 15, 2026 | 3.63M | 7.54% | +8% | 948,967 | 3.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded CRL
Since Nov 17, 2024, 3 members of Congress reported 3 purchases and 2 sales of CRL. The latest was a sale by Robert P. Bresnahan, Jr. on May 15, 2025, reported May 31, 2025.
Purchases 3Sales 2
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| May 15, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Sale | $1K–$15K | Self | May 31, 2025 | Report |
| May 12, 2025 | Jefferson Shreve (R-IN) | Sale | $15K–$50K | Self | Jun 22, 2025 | Report |
| May 8, 2025 | Jefferson Shreve (R-IN) | Purchase | $15K–$50K | Self | Jun 22, 2025 | Report |
| Apr 8, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Purchase | $15K–$50K | Self | May 8, 2025 | Report |
| Jan 15, 2025 | Julie Johnson (D-TX) | Purchase | $1K–$15K | Joint | Feb 12, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Charles River Laboratories International company events
Charles River Laboratories International filed 13 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026AnnouncementShared information with investors. Filing
- Nov 4, 2026ResultsReleased financial results. Filing
- Sep 24, 2026AnnouncementShared information with investors. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- May 11, 2026LeadershipCharles River Laboratories International, Inc. held its 2026 annual meeting of shareholders. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Feb 25, 2026AnnouncementShared information with investors. Filing
- Feb 18, 2026LeadershipThe Company announced the appointment of Glenn Coleman as its Corporate Executive Vice President and Chief Financial Officer. Filing
- Feb 18, 2026ResultsReleased financial results. Filing
- Jan 13, 2026ResultsReleased financial results. Filing
- Jan 9, 2026LeadershipThe Board of Directors of Charles River Laboratories International, Inc. announced a leadership transition plan. Filing
- Dec 3, 2025AnnouncementShared information with investors. Filing
- Nov 17, 2025AnnouncementAs previously disclosed, on May 16, 2023, Charles River Laboratories International, Inc., (Company) received an inquiry from the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) requesting it to voluntarily provide information, subsequently augmented with a document… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Charles River Laboratories International financials
Famous investors that hold CRL
6 of the 50 well-known investors we track reported holding CRL in their latest 13F filing. The largest position is Bill Nygren's, worth $416M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Bill Nygren · Harris Associates (Oakmark) | Q3 2026 | 1.41M | $416M | 0.5% | -37% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 503,074 | $148M | 0.1% | -58% |
| Israel Englander · Millennium Management | Q3 2026 | 331,541 | $97.8M | 0.1% | -32% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 70,553 | $20.8M | 0.1% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 44,921 | $13.3M | 0.1% | New |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 955 | $282K | 0.0% | -5% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named CRL in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G | 6.3% |
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G | 6.3% |
| Nov 10, 2026 | Invesco Ltd. | 13G/A | 3.9% |
| Nov 10, 2026 | Invesco Ltd. | 13G/A | 3.9% |
| Nov 5, 2026 | FMR LLC | 13G/A | 12.4% |
| Nov 5, 2026 | FMR LLC | 13G/A | 12.4% |
Questions about Charles River Laboratories International, Inc. (CRL) stock
Who owns the most CRL stock?
The largest reported owner of Charles River Laboratories International, Inc. (CRL) is FMR LLC (Fidelity), with 8.8% of the company. In total, 565 funds and institutions reported holding CRL at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are CRL insiders buying or selling?
In the last 12 months, CRL insiders reported 2 open-market purchases worth $7.3K and 21 sales worth $52.1M. The latest trade was on Oct 22, 2026. See every trade.
What is the short interest in CRL?
As of Oct 30, 2026, 2.99M CRL shares were sold short, 6.2% of the shares outstanding, up 5.4% from the report before. At the average daily volume of 1.34M shares, buying them all back would take about 2.2 trading days (days to cover). See the history.
Have members of Congress traded CRL?
Yes. 3 members of Congress reported 3 purchases and 2 sales of CRL since Nov 17, 2024. The latest was reported on Jun 22, 2025. See the trades.
Which famous investors hold CRL?
6 of the 50 well-known investors we track reported CRL in their latest 13F filing, including Bill Nygren, Ken Griffin, Israel Englander. The largest position is worth $416M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.